
Prince Akwasi Mensah
Examiner (ID: 16550, Phone: (571)270-7183 , Office: P/2474 )
| Most Active Art Unit | 2474 |
| Art Unit(s) | 2416, 2474 |
| Total Applications | 590 |
| Issued Applications | 431 |
| Pending Applications | 63 |
| Abandoned Applications | 119 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 8006181
[patent_doc_number] => 08084491
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-12-27
[patent_title] => 'Treatments for wound healing'
[patent_app_type] => utility
[patent_app_number] => 11/830906
[patent_app_country] => US
[patent_app_date] => 2007-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 27
[patent_no_of_words] => 10279
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/084/08084491.pdf
[firstpage_image] =>[orig_patent_app_number] => 11830906
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/830906 | Treatments for wound healing | Jul 30, 2007 | Issued |
Array
(
[id] => 5029034
[patent_doc_number] => 20070270481
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-11-22
[patent_title] => 'Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases'
[patent_app_type] => utility
[patent_app_number] => 11/882109
[patent_app_country] => US
[patent_app_date] => 2007-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2888
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0270/20070270481.pdf
[firstpage_image] =>[orig_patent_app_number] => 11882109
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/882109 | Combination of anticholineric and β mimetics for the treatment of respiratory diseases | Jul 29, 2007 | Issued |
Array
(
[id] => 5490812
[patent_doc_number] => 20090291883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-26
[patent_title] => 'COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT DISEASE'
[patent_app_type] => utility
[patent_app_number] => 12/373841
[patent_app_country] => US
[patent_app_date] => 2007-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 24898
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0291/20090291883.pdf
[firstpage_image] =>[orig_patent_app_number] => 12373841
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/373841 | COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT DISEASE | Jul 15, 2007 | Abandoned |
Array
(
[id] => 8410366
[patent_doc_number] => 08273763
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-09-25
[patent_title] => 'Drugs for the treatment of sarcoglycanopathies'
[patent_app_type] => utility
[patent_app_number] => 12/374317
[patent_app_country] => US
[patent_app_date] => 2007-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 13
[patent_no_of_words] => 5392
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12374317
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/374317 | Drugs for the treatment of sarcoglycanopathies | Jul 15, 2007 | Issued |
Array
(
[id] => 8543501
[patent_doc_number] => 08318792
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-11-27
[patent_title] => 'Therapeutic agent for amyotrophic lateral sclerosis'
[patent_app_type] => utility
[patent_app_number] => 12/374187
[patent_app_country] => US
[patent_app_date] => 2007-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 23
[patent_no_of_words] => 19641
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12374187
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/374187 | Therapeutic agent for amyotrophic lateral sclerosis | Jul 12, 2007 | Issued |
Array
(
[id] => 5496455
[patent_doc_number] => 20090264483
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-10-22
[patent_title] => 'METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER'
[patent_app_type] => utility
[patent_app_number] => 12/373823
[patent_app_country] => US
[patent_app_date] => 2007-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 12654
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0264/20090264483.pdf
[firstpage_image] =>[orig_patent_app_number] => 12373823
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/373823 | METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | Jul 9, 2007 | Abandoned |
Array
(
[id] => 5380325
[patent_doc_number] => 20090192164
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-07-30
[patent_title] => 'Treating agent of inflammatory bowel disease'
[patent_app_type] => utility
[patent_app_number] => 12/308750
[patent_app_country] => US
[patent_app_date] => 2007-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9001
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0192/20090192164.pdf
[firstpage_image] =>[orig_patent_app_number] => 12308750
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/308750 | Treating agent of inflammatory bowel disease | Jun 25, 2007 | Abandoned |
Array
(
[id] => 6424525
[patent_doc_number] => 20100168078
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-07-01
[patent_title] => 'S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS'
[patent_app_type] => utility
[patent_app_number] => 12/303765
[patent_app_country] => US
[patent_app_date] => 2007-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5724
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0168/20100168078.pdf
[firstpage_image] =>[orig_patent_app_number] => 12303765
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/303765 | S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | Jun 24, 2007 | Abandoned |
Array
(
[id] => 4786208
[patent_doc_number] => 20080139537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-06-12
[patent_title] => 'CGRP Antagonists'
[patent_app_type] => utility
[patent_app_number] => 11/760057
[patent_app_country] => US
[patent_app_date] => 2007-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3065
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0139/20080139537.pdf
[firstpage_image] =>[orig_patent_app_number] => 11760057
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/760057 | CGRP antagonists | Jun 7, 2007 | Issued |
Array
(
[id] => 5126478
[patent_doc_number] => 20070238749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-10-11
[patent_title] => 'Alpha2delta ligands for the treatment of fibromyalgia and other disorders'
[patent_app_type] => utility
[patent_app_number] => 11/804789
[patent_app_country] => US
[patent_app_date] => 2007-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8951
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0238/20070238749.pdf
[firstpage_image] =>[orig_patent_app_number] => 11804789
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/804789 | Alpha2delta ligands for the treatment of fibromyalgia and other disorders | May 17, 2007 | Abandoned |
Array
(
[id] => 5343330
[patent_doc_number] => 20090181980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-07-16
[patent_title] => 'Synergistic Pharmaceutical Composition'
[patent_app_type] => utility
[patent_app_number] => 12/299805
[patent_app_country] => US
[patent_app_date] => 2007-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 2955
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0181/20090181980.pdf
[firstpage_image] =>[orig_patent_app_number] => 12299805
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/299805 | Synergistic Pharmaceutical Composition | May 8, 2007 | Abandoned |
Array
(
[id] => 5398351
[patent_doc_number] => 20090318414
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-24
[patent_title] => 'Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome'
[patent_app_type] => utility
[patent_app_number] => 12/226423
[patent_app_country] => US
[patent_app_date] => 2007-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4570
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0318/20090318414.pdf
[firstpage_image] =>[orig_patent_app_number] => 12226423
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/226423 | Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome | Apr 22, 2007 | Abandoned |
Array
(
[id] => 4461031
[patent_doc_number] => 07879870
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-02-01
[patent_title] => 'Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists'
[patent_app_type] => utility
[patent_app_number] => 11/735548
[patent_app_country] => US
[patent_app_date] => 2007-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 11
[patent_no_of_words] => 9254
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/879/07879870.pdf
[firstpage_image] =>[orig_patent_app_number] => 11735548
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/735548 | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | Apr 15, 2007 | Issued |
Array
(
[id] => 5392252
[patent_doc_number] => 20090209565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-20
[patent_title] => 'THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE'
[patent_app_type] => utility
[patent_app_number] => 12/296671
[patent_app_country] => US
[patent_app_date] => 2007-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 3953
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0209/20090209565.pdf
[firstpage_image] =>[orig_patent_app_number] => 12296671
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/296671 | Therapeutic agent for inflammatory bowel disease | Apr 11, 2007 | Issued |
Array
(
[id] => 5231435
[patent_doc_number] => 20070293543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-12-20
[patent_title] => 'THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z'
[patent_app_type] => utility
[patent_app_number] => 11/734691
[patent_app_country] => US
[patent_app_date] => 2007-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 448
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0293/20070293543.pdf
[firstpage_image] =>[orig_patent_app_number] => 11734691
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/734691 | THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z | Apr 11, 2007 | Abandoned |
Array
(
[id] => 7687424
[patent_doc_number] => 20090176867
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-07-09
[patent_title] => 'USE OF N-(DIBENZ(B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF FOR THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY'
[patent_app_type] => utility
[patent_app_number] => 12/295801
[patent_app_country] => US
[patent_app_date] => 2007-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 3612
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0176/20090176867.pdf
[firstpage_image] =>[orig_patent_app_number] => 12295801
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/295801 | N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency | Apr 3, 2007 | Issued |
Array
(
[id] => 5063634
[patent_doc_number] => 20070225274
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-09-27
[patent_title] => 'Methods for modulating bladder function'
[patent_app_type] => utility
[patent_app_number] => 11/728107
[patent_app_country] => US
[patent_app_date] => 2007-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6796
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0225/20070225274.pdf
[firstpage_image] =>[orig_patent_app_number] => 11728107
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/728107 | Methods for modulating bladder function | Mar 22, 2007 | Abandoned |
Array
(
[id] => 5374797
[patent_doc_number] => 20090312358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-17
[patent_title] => 'METHOD FOR MANAGEMENT OF DIARRHEA'
[patent_app_type] => utility
[patent_app_number] => 12/294003
[patent_app_country] => US
[patent_app_date] => 2007-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21953
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0312/20090312358.pdf
[firstpage_image] =>[orig_patent_app_number] => 12294003
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/294003 | METHOD FOR MANAGEMENT OF DIARRHEA | Mar 21, 2007 | Abandoned |
Array
(
[id] => 5447099
[patent_doc_number] => 20090048325
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-02-19
[patent_title] => 'Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome'
[patent_app_type] => utility
[patent_app_number] => 12/225269
[patent_app_country] => US
[patent_app_date] => 2007-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 10831
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0048/20090048325.pdf
[firstpage_image] =>[orig_patent_app_number] => 12225269
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/225269 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | Mar 18, 2007 | Abandoned |
Array
(
[id] => 24016
[patent_doc_number] => 07795268
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-09-14
[patent_title] => 'Method of treating hepatic disease using A2B adenosine receptor antagonists'
[patent_app_type] => utility
[patent_app_number] => 11/687236
[patent_app_country] => US
[patent_app_date] => 2007-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 21866
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/795/07795268.pdf
[firstpage_image] =>[orig_patent_app_number] => 11687236
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/687236 | Method of treating hepatic disease using A2B adenosine receptor antagonists | Mar 15, 2007 | Issued |